معرفی
B. Hilda Ye is an Associate Professor in the Department of Cell Biology at Albert Einstein College of Medicine. Her research focuses on understanding how transcriptional regulation and cell signaling govern lymphocyte differentiation and lymphoma development, with a current emphasis on diffuse large B-cell lymphoma (DLBCL) and adult T-cell leukemia/lymphoma (ATLL). Her work bridges molecular pathogenesis, cancer genetics, and tumor-host interactions to uncover mechanisms underlying lymphomagenesis and therapeutic resistance.
Her research program investigates three key areas: molecular mechanisms of B and T cell development, perturbations in these processes during lymphoma formation, and the development of mechanism-based therapies. Notably, her lab has elucidated roles for BCL6, STAT3, and the IL-6/Jak/STAT3 pathway in DLBCL, and recently shifted focus to ATLL, particularly its genomic and clinical differences between North American and Japanese cohorts. This includes studying epigenetic mutations, immune evasion strategies, and the potential of epigenetic therapies.
Her publications highlight advancements in understanding HTLV-1-driven ATLL pathogenesis, genomic landscapes of ATLL, and therapeutic approaches targeting PAK kinase and immune checkpoint pathways. Collaborations with clinical groups at Montefiore Medical Center leverage unique access to patient samples for translational studies.
Research trends in her articles emphasize genomic profiling, immune modulation, and targeted therapies for hematologic malignancies. Her work underscores the importance of integrating molecular, genetic, and clinical data to address unmet therapeutic needs in T-cell malignancies.
Labs and teams: Her laboratory at Albert Einstein College of Medicine focuses on ATLL and lymphoma biology, with ongoing studies on BCL6’s role in ATLL identity, genomic evolution between ATLL subtypes, and overcoming immunosuppression in ATLL patients.
